World Cancer Research Conference

Oct 19-20, 2020


San Francisco, United States of America

LexisConferences invites all the participants from all over the world to attend “World Cancer Research Conferences” during October 19-20, 2020 in San FranciscoUSA.

This conference will offer you uncommon prospects to arrange with Academic and Clinical oncology Specialists, Clinical oncology Researchers, Medical Research Departments, Faculty of Health Sciences, C-level authority, Faculty of Healthcare, Deans, Professors and PhD Students from Medical Universities. It is an overall stage to look at and get some answers concerning Fostering and Latest Innovations in Cancer Diagnosis. Biomarkers on the other hand , give a dynamic and incredible way to deal with understanding the range of ailments with evident applications in systematic the study of disease transmission, biomarkers and clinical research in sickness avoidance, conclusion and illness the executives. Biomarkers have the extra potential to recognize people powerless to specific sicknesses. In the on-going years, the data about malignancy biomarkers has expanded to a great extent giving an immense potential to enhancing the administration of disease patients by enhancing the exactness of recognition and viability of treatment. This meeting additionally incorporates symposia and workshop occasions and especially urge to spread the information of steady disclosures and logical research refreshes in nowadays.

Market Analysis:

Cancer profiling market has extended to reach USD 12.4 billion by 2024 from USD 7.5 billion in 2019, at a CAGR of 10.5%. Growth in this market is determined by the growing incidences of cancer across the globe and the increasing use of biomarkers in tumor profiling. Other market drivers include an increase in cancer research & funding and technological advancements in profiling technologies.

Market Dynamics:

Increasing incidence of cancer

According to the WHO, cancer is the second-leading cause of death, globally, and was responsible for an estimated 9.6 million deaths in 2018. According to the Cancer Research UK report, an estimated 23.6 million new cases of cancer will be reported in 2030, up from 18.1 million in 2018. More than 60% of the new cancer cases occur in Africa, Asia, and Central and South America; 70% of the global cancer deaths also occur in these regions.

The use of biomarkers can significantly increase the exactness of cancer diagnosis, which in turn reduces the cost of treatment. Biomarker-based cancer detection profiles the disease at the molecular level, which provides more accurate information about cancer compared to other detection methods such as barium enema (detects colon and rectal cancer) and cystoscopy. Similarly, liquid biopsy holds several benefits over traditional cancer diagnostic techniques, such as reduced costs, early prognosis, therapy monitoring, detection of heterogeneity, effective against acquired drug resistance, and patient comfort (by eliminating the need for surgery). Such molecular profiles of the patients aid in better understanding the suitable treatment regime along with the recurrence risk, thereby improving patient care.

High Capital Investment:

Within the present paradigm of customized drugs or preciseness drugs, several analysis efforts square measure aimed toward distinctive novel biomarkers. Significant capital investments are required for the discovery, development, and validation of biomarkers used in cancer detection and prognosis. Once a candidate biomarker is developed, the evidence is required for its adoption in the clinical field. The discovery of candidate biomarkers way outpaces the present ability to validate them. Akin to clinical trials for prescribed drugs, translational research is a long and complex trajectory requiring large financial investments, and results in the rejection of a number of biomarker candidates. An estimated cost for the development and commercialization of a new biomarker-based diagnostic technology exceeds over USD 100 million.Such immense investments to run clinical trials and address demanding restrictive necessities not solely affects the power of tiny firms to develop biomarkers however additionally severely affects innovation. This is a significant issue restraining the expansion of the biomarkers market and alternative connected markets like medical specialty (in vitro medical specialty or companion diagnostics) and customized drugs.

The APAC market is expected to grow at the highest CAGR during the forecast period

Cancer profiling market in the Asia Pacific is expected to grow at the highest CAGR during the forecast period. The high incidence of cancer, increasing proteomics & genomics research, growing research funding, rising investments by pharmaceutical & biotechnology companies, and awareness about personalized therapeutics in the region are propelling the market growth.